The Influence of Toll-like Receptor (TLR-) Agonists on Lysozyme Activity and TNFα-Secretion in THP-1 cells

Schopohl, Patrick; Melzig, MF

doi:10.1055/s-0033-1352441

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These differentiated cells (pTHP-1 cells) have been reported to display unique characteristics compared with parental nTHP-1 cells, including increased phagocytic activity, altered expression of Toll-like receptors (TLR), and re-wiring of mitogen-activated protein kinase (MAPK) pathways (Schwende et al 1996;Daigneault et al 2010;Richter et al 2016). Distinct reactivity of nTHP-1 and pTHP-1 cells have been reported when each cell type was treated with immunostimulatory agents like Pam3CSK4 (Daigneault et al 2010), lipopolysaccharide (LPS) (Schopohl and Melzig 2014), and forskolin (Higashi et al 2008). Therefore, both nTHP-1 and pTHP-1 cells were used here to examine the immunostimulatory properties of the peptide or protein pharmaceuticals used in this study.…”

Section: Discussionmentioning

confidence: 99%

“…THP-1 cells are known to differentiate into macrophage-like cells upon phorbol myristate acetate (PMA) treatment and to exhibit distinct reactivity to immunostimulatory agents (Schwende et al 1996;Schopohl and Melzig 2014). To establish an assay platform for evaluating potential risk of immune-mediated ISR from peptide or protein pharmaceuticals, immunostimulatory properties of three types of peptide or protein pharmaceuticals were evaluated using THP-1 cells with or without PMA pre-treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunostimulatory effects on THP-1 cells by peptide or protein pharmaceuticals associated with injection site reactions

Hamamura-Yasuno

Aida

Tsuchiya

et al. 2020

Journal of Immunotoxicology

View full text Add to dashboard Cite

Injection site reaction (ISR) is a common side-effect associated with the use of peptide or protein pharmaceuticals. These types of pharmaceuticals-induced activation of antigen-presenting cells is assumed to be a key step in the pathogenesis of immune-mediated ISR. The present study was designed to evaluate the immunostimulatory properties of peptide or protein pharmaceuticals using human monocytic THP-1 cells. Here, THP-1 cells, with or without phorbol-12-myristate-13-acetate (PMA) pretreatment, were exposed to enfuvirtide and glatiramer acetate (positive controls) or evolocumab (negative control) for 6 or 24 h. PMA treatment differentiated non-adherent monocytic THP-1 (nTHP-1) cells into adherent macrophagic THP-1 (pTHP-1) cells that highly express CD11b and CD36. Enfuvirtide increased the release of cytokines, e.g. TNFa, MIP-1b, and MCP-1, and expression of CD86 and CD54 on nTHP-1 cells at 24 h. Similar immunostimulatory properties of glatiramer acetate were observed both in the nTHP-1 and pTHP-1 cells at 6 h, but the responses were very weak in the pTHP-1 cells. Evolocumab did not affect cytokine secretion or cell surface marker expression in either cell type. Taken together, these in vitro THP-1 cell assays revealed the immunostimulatory properties of enfuvirtide and glatiramer acetate. This assay platform thus could serve as a powerful tool in evaluating potential immune-related ISR risks of peptide or protein pharmaceuticals in humans.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Immunostimulatory effects on THP-1 cells by peptide or protein pharmaceuticals associated with injection site reactions

Hamamura-Yasuno

Aida

Tsuchiya

et al. 2020

Journal of Immunotoxicology

View full text Add to dashboard Cite

show abstract

“…Эти взаимодействия стимулируют дифференцировку моноцитов в макрофаги и активируют незрелые дендритные клетки, что приводит к продукции хемокинов и цитокинов (интерлейкина 2, интерлейкина 10, а также интерферона γ). С увеличением активности макрофагов может быть связано и увеличение содержания вырабатываемого ими бактерицидного фермента лизоцима в биологических жидкостях [24]. В целом эти ответы способствуют рекрутированию (перемещению) врожденных эффекторных клеток на участки слизистой оболочки и индуцируют активацию и дифференцировку Т-и В-лимфоцитов.…”

Section: Conflict Of Interest: the Authors Declare No Conflict Of Int...unclassified

Efficiency of topical bacterial lysates in inflammatory diseases of the oral cavity and pharynx

Шахов

Krasilnikova

2023

Medicinskij sovet

View full text Add to dashboard Cite

Acute and chronic infectious and inflammatory diseases of the upper respiratory tract occupy one of the leading places in the structure of morbidity of the population of the world and remain the most frequent cause of patients seeking medical care. The prevalence and frequency of respiratory infectious diseases make a significant contribution to the structure of the causes of temporary disability, which entails negative socio-economic consequences. Specific attention in the current epidemic season is attracted by the change in the traditional structure of pathogens associated with several strict anti-epidemic measures during the COVID-19 pandemic, as well as a decrease in the activity of other pathogens during the active circulation of SARS-CoV-2. In this aspect, the increased resistance of pathogens to etiotropic drugs and insufficiency of the arsenal of pathogenic drugs dictate the need to search for alternative approaches to the treatment of inflammatory diseases of the mouth and throat. The main purpose of non-specific preventive measures of acute and recurrent diseases of the oral cavity and pharynx is to reduce bacterial content of mucous membranes by various pathogens and to activate own protective anti-infective mechanisms. In clinical practice medicines which contain bacterial lysates are considered to be an effective part of treatment of upper respiratory tract’s inflammatory diseases. They allow achieving elimination of a pathogenic organism and also help to restore autoregulation of immune response in the whole organism, reduce the frequency of infectious diseases. Topical bacterial lysates, acting directly in the locus of inflammation, do not harm the human microbiome, have a high safety profile, combine well with other medicines and can be used for patients of different ages. Topical immunotherapy has a significant preventive effect, preventing possible complications and improving the quality of life. The use of Imudon and IRS 19 leads to positive clinical and immunological shifts and promotes the efficiency of rehabilitation and preventive measures.

show abstract

The Influence of Toll-like Receptor (TLR-) Agonists on Lysozyme Activity and TNFα-Secretion in THP-1 cells

Cited by 2 publications

References 0 publications

Immunostimulatory effects on THP-1 cells by peptide or protein pharmaceuticals associated with injection site reactions

Immunostimulatory effects on THP-1 cells by peptide or protein pharmaceuticals associated with injection site reactions

Efficiency of topical bacterial lysates in inflammatory diseases of the oral cavity and pharynx

Contact Info

Product

Resources

About